|
|
|
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, November 12th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and...
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM,...
NightHawk Radiology Holdings, Inc. (NASDAQ: NHWK) 26% LOWER; reports Q3 EPS of $0.17, ex-items, 1 cent better than the analyst estimate of $0.16. Revenue for the quarter was $43.5 million, which compares to the estimate of...
Palifosfamide prolongs progression-free survival by at least 50% -- Palifosfamide is easily administered as an out-patient treatment, and generally well-tolerated. ”These interim results are very promising, indicating a...
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 6th Annual Merriman, Curhan, Ford Investor Summit on Tuesday, November 10, 2009 at 12:20 pm ET at...
The 2009 BIO Investor Forum takes place Oct. 28 - Business Wire is the official news wire for the 2009 BIO Investor Forum. Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business...
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 8 th Annual BIO Investor Forum on Thursday, October 29, 2009 at 10:00 am PT at the Palace Hotel...
67 WALL STREET, New York - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. Gene Delivery Technology Companies include:...
China INSOnline Corp. (NASDAQ: CHIO) 40% HIGHER; reports FY09 EPS of $0.23, compared to $0.25 in the same quarter last year. Revenue for the fiscal year was $17.9 million, versus $13.7 million in FY08. Active Power, Inc....
Associated Press, 10.14.09, 12:16 PM EDT NEW YORK -- Ziopharm Oncology Inc. stopped enrollment in a mid-stage clinical study of its cancer treatment Zymafos, saying the study was a success. The study compared a combination of...
